Scotland's largest cancer centre, named after the surgeon who first used endocrine therapy for breast cancer, next to a leading cancer biology institute.
The Beatson West of Scotland Cancer Centre at Gartnavel is the tertiary oncology centre for the west of Scotland and one of the largest in the UK. It takes its name from Sir George Beatson, who in 1896 reported that removing the ovaries could shrink advanced breast cancer, the first endocrine therapy. The adjacent Cancer Research UK Scotland Institute (formerly the Beatson Institute, founded 1967) under Owen Sansom is known for genetically engineered mouse models of colorectal and pancreatic cancer, cancer metabolism and cell death research, and the University of Glasgow's Wolfson Wohl Cancer Research Centre hosts Andrew Biankin's Precision-Panc programme for pancreatic cancer. Patients have access to a large radiotherapy service, early-phase trials and Scotland's molecular pathology network.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Beatson West of Scotland Cancer Centre, including child institutions. 258 works · 2,699 citations · 75% open access · 19% clinical trials · 0% reviews.
Glasgow cancer biologist who directs the CRUK Scotland Institute and is Scientific Director of the CRUK Scotland Centre, known for mouse models of colorectal and pancreatic cancer.
Clinical Director of specialist oncology services at the Beatson West of Scotland Cancer Centre, Scotland's largest cancer treatment centre.
Shares Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow Royal Infirmary, Precision-Panc, KRAS.
Shares Edinburgh Cancer Centre / CRUK Scotland Centre, AMMF, the Cholangiocarcinoma Charity, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma.
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma.
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, Cancer Research UK, Pancreatic ductal adenocarcinoma.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer, Prostate cancer.
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, Pancreatic ductal adenocarcinoma.
Shares Estrogen receptor (ERα), KRAS, Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer.
Shares Patient-derived xenografts, KRAS & RAS inhibitors, KRAS, HR-positive / HER2-negative breast cancer.